iTeos Therapeutics, Inc. Stock
Stocks
ITOS
US46565G1040
Biotechnology & Medical Research
| 1 day | +0.20% |
| Manager | Title | Age | Since |
|---|---|---|---|
Ryan Cole
COO | Chief Operating Officer | - | 2025-08-27 |
Katie George
CTO | Chief Tech/Sci/R&D Officer | - | - |
David Feltquate
CTO | Chief Tech/Sci/R&D Officer | 57 | 2024-08-04 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 8/29/25 | Tender | Chief Technology Officer | 222,423 | 0.5811% | ||
| 8/29/25 | Tender | Chief Executive Officer; Director | 1,106,638 | 2.8914% | ||
| 8/29/25 | Tender | Chief Operating Officer | 578,671 | 1.5119% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.20% | -0.39% | - | - | 449M | |
| -2.69% | -0.48% | +51.67% | +69.09% | 66.33B | |
| -0.92% | +7.67% | +14.26% | +90.92% | 60.62B | |
| 0.00% | +0.39% | +20.52% | +98.45% | 55.5B | |
| +0.14% | +2.35% | +13.08% | +109.47% | 47.58B | |
| -2.21% | -2.47% | +18.60% | +36.89% | 43.69B | |
| -2.30% | -10.40% | +167.61% | +776.79% | 37.27B | |
| +2.15% | +1.42% | +15.17% | +56.49% | 36.57B | |
| -2.32% | -2.24% | +75.52% | +52.70% | 32.22B | |
| +2.62% | +5.90% | -36.55% | +406.95% | 26.58B | |
| Average | -0.53% | +0.05% | +37.76% | +188.64% | 45B | |
| Weighted average by Cap. | -0.83% | +0.20% | +37.23% | +162.19% |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
